<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mediators Inflamm</journal-id><journal-title>Mediators of Inflammation</journal-title><issn pub-type="ppub">0962-9351</issn><issn pub-type="epub">1466-1861</issn><publisher><publisher-name>Hindawi Publishing Corporation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">18475734</article-id><article-id pub-id-type="pmc">2365805</article-id>
		<article-id pub-id-type="pii">S0962935196000555</article-id>
		<article-id pub-id-type="doi">10.1155/S0962935196000555</article-id>
	<article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>A blinded comparison of fluticasone propionate with budesonide via powder devices in adult patients with moderate-to-severe asthma: a clinical evaluation</article-title></title-group><contrib-group>
		<contrib contrib-type="author"><name><surname>Ringdal</surname><given-names>N.</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib>
		<contrib contrib-type="author"><name><surname>Swinburn</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib>
		<contrib contrib-type="author"><name><surname>Backman</surname><given-names>R.</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib>
		<contrib contrib-type="author"><name><surname>Plaschke</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib>
		<contrib contrib-type="author"><name><surname>Sips</surname><given-names>A. P.</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib>
		<contrib contrib-type="author"><name><surname>Kjaersgaard</surname><given-names>P.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib>
		<contrib contrib-type="author"><name><surname>Bratten</surname><given-names>G.</given-names></name><xref ref-type="aff" rid="aff6">6</xref></contrib>
		<contrib contrib-type="author" corresp="yes"><name><surname>Harris</surname><given-names>T. A. J.</given-names></name><xref ref-type="aff" rid="aff7">7</xref></contrib>
	</contrib-group>
		<aff id="aff1"><label>1</label>
			<addr-line>Molde County Hospital</addr-line>
			<country>Norway</country>
		</aff>
		<aff id="aff2"><label>2</label>
			<addr-line>Mercy Specialist Centre</addr-line>
			<country>New Zealand</country>
		</aff>
		<aff id="aff3"><label>3</label>
			<addr-line>Meltola Hospital</addr-line>
			<country>Finland</country>
		</aff>
		<aff id="aff4"><label>4</label>
			<addr-line>Sahlgren's Hospital</addr-line>
			<country>Sweden</country>
		</aff>
		<aff id="aff5"><label>5</label>
			<addr-line>The Polikliniek Kanalweg</addr-line>
			<country>The Netherlands</country>
		</aff>
		<aff id="aff6"><label>6</label>
			<addr-line>Glaxo Wellcome AS</addr-line>
			<country>Norway</country>
		</aff>
		<aff id="aff7"><label>7</label>
			<addr-line>International Medical Affairs</addr-line>
			<addr-line>Glaxo Wellcome</addr-line>
			<country>UK</country>
		</aff>
	<pub-date pub-type="ppub"><month>10</month><year>1996</year></pub-date><volume>5</volume><issue>5</issue><fpage>382</fpage><lpage>389</lpage><permissions><copyright-statement>Copyright &#x000a9; 1996 Hindawi Publishing Corporation.</copyright-statement><copyright-year>1996</copyright-year><copyright-holder>Hindawi Publishing Corporation</copyright-holder><license license-type="open-access" xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://creativecommons.org/licenses/by/"><p>This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license></permissions><abstract>
		<p>
			<italic>In Vitro</italic> and <italic>in vivo</italic> data have demonstrated that there are detectable differences between inhaled corticosteroids commonly used to treat asthma. However, controversy still remains as to whether these differences translate into clinical benefits. This 12-week, international, randomized, doubleblind, parallel-group study was undertaken to compare the efficacy and safety of fluticasone propionate (FP) 800 &#x003bc;g daily, administered as a powder via the Diskhaler<sup>&#x000ae;</sup>, and budesonide (BUD) 1600 &#x003bc;g daily, administered using the Turbuhaler<sup>&#x000ae;</sup>, in adult patients with moderate-tosevere asthma. A total of 518 patients participated in the study, 256 of whom received FP and 262 BUD. Assessment of mean morning peak expiratory flow (PEF) over the 12-week treatment period revealed a statistically significant difference in efficacy between FP 800 &#x003bc;g daily and BUD 1600 &#x003bc;g daily in favour of FP (<italic>p</italic> = 0.003), with an overall improvement of 20.9 l/min with FP compared with 12.4 l/min on BUD. Statistically significant differences in favour of FP were seen over the 12 weeks for mean evening PEF (<italic>p</italic> = 0.04), diurnal PEF variation (<italic>p</italic> = 0.03) and percentage predicted PEF (<italic>p</italic> = 0.003), as well as forced expiratory volume (<italic>p</italic> = 0.008), forced vital capacity (<italic>p</italic> = 0.02) and PEF (<italic>p</italic> = 0.005) measured at clinic visits. The median percentage of symptom-free nights increased over the 12-week study period in both treatment groups, with similar changes seen for the median percentage of days with symptom score &#x0003c; 2, rescue medication use and exacerbations of asthma. The incidence of adverse events was found to be comparable in the two treatment groups. The geometric mean ratios of serum cortisol levels were found to be 1.03 for FP, indicating no mean hypothalamic-pituitary-adrenal axis suppression from baseline, and 0.93 for BUD (<italic>p</italic> = 0.0002 compared with FP). In summary, FP 800 &#x003bc;g daily showed a greater efficacy/safety ratio in the treatment of moderate-to-severe asthma than BUD 1600 &#x003bc;g daily.</p>
	</abstract></article-meta></front></article>


